CD19 and acute lymphoblastic leukemia: Although complete tumor regression (70–90% for B-cell acute lymphoblastic leukemia [B-ALL]) can be achieved in a substantial fraction of patients, anti-CD19 CAR-T cell therapy has also suffered resistance in some cases because of the loss of expression of the antigen (5, 6, 7, 8).